Rocky Mountain Spotted Fever (Rickettsia rickettsii)
Overview
Plain-Language Overview
Rocky Mountain Spotted Fever (RMSF) is a serious illness caused by a bacterial infection that affects the blood vessels. It is transmitted through the bite of an infected tick, which introduces the bacteria into the bloodstream. The infection primarily targets the lining of small blood vessels, leading to widespread inflammation. This can cause symptoms such as fever, rash, and severe headache. If untreated, the disease can affect multiple organs including the heart, lungs, and brain, potentially leading to life-threatening complications. Early recognition of symptoms is important because the infection can progress rapidly. The condition mainly impacts the circulatory system and overall body function.
Clinical Definition
Rocky Mountain Spotted Fever (RMSF) is an acute, systemic vasculitis caused by the obligate intracellular gram-negative bacterium Rickettsia rickettsii. The pathogen infects endothelial cells lining small blood vessels, leading to vascular inflammation, increased permeability, and microvascular injury. This results in characteristic clinical features including high fever, maculopapular rash that often begins on the wrists and ankles and spreads centrally, and thrombocytopenia. The disease is transmitted by tick vectors, primarily Dermacentor species. RMSF is a medical emergency due to its potential for rapid progression to multi-organ failure and death if untreated. Diagnosis relies on clinical suspicion in endemic areas combined with laboratory confirmation. Early treatment is critical to reduce morbidity and mortality.
Inciting Event
Bite from an infected Dermacentor tick transmits Rickettsia rickettsii into the bloodstream.
Tick attachment for >6 hours is typically required for effective transmission of the pathogen.
Latency Period
Symptoms typically develop 2 to 14 days after tick bite, with an average incubation of about 7 days.
Diagnostic Delay
Nonspecific early symptoms such as fever and headache mimic viral illnesses, leading to misdiagnosis.
Absence of rash in early disease delays clinical suspicion of Rocky Mountain spotted fever.
Lack of reported tick exposure or unnoticed tick bite contributes to diagnostic uncertainty.
Limited availability or delay of confirmatory serologic testing can postpone diagnosis.
Clinical Presentation
Signs & Symptoms
High fever and severe headache
Myalgias and malaise
Rash starting 2-5 days after fever onset, initially on wrists and ankles
Nausea, vomiting, and abdominal pain
Photophobia and conjunctival injection
History of Present Illness
Initial presentation includes high fever, severe headache, and myalgias.
Within 2 to 5 days, a maculopapular rash develops, often starting on the wrists and ankles and spreading centrally.
Rash may progress to petechiae and involve the palms and soles, which is characteristic.
Patients often report nausea, vomiting, and abdominal pain as systemic involvement progresses.
Severe cases may develop neurologic symptoms such as confusion or seizures due to vasculitis.
Past Medical History
Prior tick bites or history of tick-borne illnesses may be relevant.
Immunocompromised states can worsen disease severity but are not required for infection.
No specific chronic conditions are required for susceptibility.
Family History
No known heritable predisposition or familial syndromes are associated with Rocky Mountain spotted fever.
Physical Exam Findings
Maculopapular rash beginning on wrists and ankles and spreading centrally including palms and soles
Fever and tachycardia
Conjunctival injection without exudate
Petechiae in later stages indicating vascular damage
Lymphadenopathy may be present
Diagnostic Workup
Diagnostic Criteria
Diagnosis of Rocky Mountain Spotted Fever is primarily clinical, based on the presence of fever, a characteristic rash starting on the wrists and ankles, and a history of tick exposure in an endemic area. Laboratory findings often include thrombocytopenia, elevated liver enzymes, and hyponatremia. Confirmatory diagnosis is made by serologic testing using indirect immunofluorescence assay (IFA) to detect antibodies against Rickettsia rickettsii, typically showing a fourfold rise in titers between acute and convalescent sera. Polymerase chain reaction (PCR) and immunohistochemical staining of skin biopsy specimens can also support diagnosis but are less commonly used.
Pathophysiology
Key Mechanisms
Endothelial cell infection by Rickettsia rickettsii leads to vascular injury and increased vascular permeability.
Vasculitis causes microvascular leakage, resulting in edema, hypovolemia, and organ ischemia.
Immune-mediated inflammation exacerbates endothelial damage and contributes to rash development and systemic symptoms.
Disseminated intravascular coagulation (DIC) may occur due to widespread endothelial injury and activation of coagulation pathways.
| Involvement | Details |
|---|---|
| Organs | Skin manifests the characteristic maculopapular and petechial rash of Rocky Mountain spotted fever. |
Lungs can develop interstitial pneumonitis and edema secondary to endothelial damage. | |
Brain may be involved in severe cases causing meningoencephalitis due to vasculitis of cerebral vessels. | |
Kidneys can suffer acute injury from microvascular thrombosis and hypoperfusion. | |
| Tissues | Vascular endothelium is critically involved as the site of bacterial invasion and inflammation causing vasculitis. |
Skin tissue shows petechial rash due to capillary leakage and microvascular injury. | |
Lung tissue may be affected by edema and inflammation in severe cases leading to respiratory distress. | |
| Cells | Endothelial cells are the primary target of Rickettsia rickettsii, leading to vascular injury and increased permeability. |
Macrophages participate in the immune response by phagocytosing infected cells and releasing inflammatory cytokines. | |
Platelets contribute to microvascular thrombosis and petechial rash formation. | |
| Chemical Mediators | Tumor necrosis factor-alpha (TNF-α) is elevated and mediates endothelial inflammation and vascular damage. |
Interleukin-1 (IL-1) promotes fever and systemic inflammatory response in Rocky Mountain spotted fever. | |
Nitric oxide (NO) is produced by activated endothelial cells and contributes to vasodilation and increased vascular permeability. |
Treatments
Pharmacological Treatments
Doxycycline
- Mechanism:
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit of Rickettsia rickettsii.
- Side effects:
Photosensitivity
Gastrointestinal upset
Tooth discoloration in children
- Clinical role:
First-line
Non-pharmacological Treatments
Supportive care including fluid resuscitation and electrolyte management to address dehydration and systemic effects.
Hospitalization for severe cases to monitor for complications such as vasculitis and organ failure.
Prevention
Pharmacological Prevention
Doxycycline prophylaxis after high-risk tick exposure in endemic areas
Non-pharmacological Prevention
Avoidance of tick-infested areas during peak seasons
Use of protective clothing and tick repellents containing DEET
Prompt tick removal within 24 hours to reduce transmission risk
Regular skin checks for ticks after outdoor activities
Outcome & Complications
Complications
Vasculitis leading to multi-organ ischemia
Acute respiratory distress syndrome (ARDS)
Disseminated intravascular coagulation (DIC)
Neurologic complications including meningoencephalitis
Renal failure due to acute tubular necrosis
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Rocky Mountain Spotted Fever (Rickettsia rickettsii) versus Meningococcemia
Rocky Mountain Spotted Fever (Rickettsia rickettsii) | Meningococcemia |
|---|---|
Caused by Rickettsia rickettsii, an obligate intracellular gram-negative coccobacillus | Caused by Neisseria meningitidis, a gram-negative diplococcus |
Maculopapular rash begins on wrists and ankles, spreading centripetally, often involving palms and soles | Petechial rash often starts on trunk and spreads rapidly, may involve mucous membranes |
History of tick bite or exposure in endemic areas such as southeastern US | Often associated with close contact in crowded settings or outbreaks |
Positive serology or PCR for Rickettsia rickettsii | Positive blood cultures for Neisseria meningitidis |
Rocky Mountain Spotted Fever (Rickettsia rickettsii) versus Typhus (Epidemic or Murine)
Rocky Mountain Spotted Fever (Rickettsia rickettsii) | Typhus (Epidemic or Murine) |
|---|---|
Caused by Rickettsia rickettsii | Caused by Rickettsia prowazekii or Rickettsia typhi |
Rash starts on wrists and ankles and spreads centripetally, involving palms and soles | Rash starts on trunk and spreads centrifugally, sparing palms and soles |
Associated with tick exposure in wooded or grassy areas | Associated with lice or fleas in crowded, unsanitary conditions |
Typically acute onset with fever, headache, and rash within 2 weeks of tick bite | Often more prolonged and severe in epidemic typhus with possible CNS involvement |
Rocky Mountain Spotted Fever (Rickettsia rickettsii) versus Kawasaki Disease
Rocky Mountain Spotted Fever (Rickettsia rickettsii) | Kawasaki Disease |
|---|---|
Can affect all ages but more common in children and adults in endemic areas | Primarily affects children under 5 years old |
Maculopapular rash with characteristic involvement of palms and soles | Polymorphous rash often with mucous membrane changes and conjunctivitis |
Thrombocytopenia and elevated liver enzymes may be present | Elevated inflammatory markers with thrombocytosis in subacute phase |
Responds to doxycycline antibiotic therapy | Responds to intravenous immunoglobulin and aspirin |
Rocky Mountain Spotted Fever (Rickettsia rickettsii) versus Disseminated Gonococcal Infection
Rocky Mountain Spotted Fever (Rickettsia rickettsii) | Disseminated Gonococcal Infection |
|---|---|
Caused by Rickettsia rickettsii | Caused by Neisseria gonorrhoeae, a gram-negative diplococcus |
Maculopapular rash involving palms and soles | Pustular or vesiculopustular lesions mainly on distal extremities |
Associated with tick bite in endemic geographic regions | Associated with recent sexual contact |
Positive serology or PCR for Rickettsia rickettsii | Positive culture or nucleic acid amplification test from mucosal sites |
Rocky Mountain Spotted Fever (Rickettsia rickettsii) versus Rocky Mountain Spotted Fever-like Illness (Other Rickettsial Diseases)
Rocky Mountain Spotted Fever (Rickettsia rickettsii) | Rocky Mountain Spotted Fever-like Illness (Other Rickettsial Diseases) |
|---|---|
Caused by Rickettsia rickettsii | Caused by other Rickettsia species such as Rickettsia akari or Rickettsia parkeri |
Diffuse maculopapular rash with characteristic distribution | Rash may be milder or localized, sometimes with eschar at bite site |
Exposure to Dermacentor ticks in southeastern and south-central US | Exposure to mites or different tick species in distinct geographic areas |
Potentially severe illness with high mortality if untreated | Usually milder illness with lower mortality |